My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Candid Therapeutics, Inc.

Candid Therapeutics Recognized as a 2025 Endpoints 11 Honoree
From Candid Therapeutics, Inc.
Via Business Wire
Candid Therapeutics to Participate in Investor and Policy Conferences
From Candid Therapeutics, Inc.
Via Business Wire
Candid Therapeutics Advances Portfolio of Novel T-Cell Engagers into Five Autoimmune Diseases for Clinical Evaluation
From Candid Therapeutics, Inc.
Via Business Wire
Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-cell Engager
From Candid Therapeutics, Inc.
Via Business Wire
Candid Therapeutics and Ab Studio Enter Into Research Collaboration to Discover and Develop Novel T Cell Engagers for Autoimmune Indications
From Candid Therapeutics, Inc.
Via Business Wire
Candid Therapeutics and EpimAb Biotherapeutics Enter Into Research Collaboration to Discover and Develop Novel T-Cell Engagers for Autoimmune Indications
From Candid Therapeutics, Inc.
Via Business Wire
Candid Therapeutics Appoints Highly Accomplished Industry Leaders Angie You, Ph.D. and Dan Puckett to it’s Board of Directors
From Candid Therapeutics, Inc.
Via Business Wire
Candid Therapeutics Debuts with $370M Capital Raise to Clinically Evaluate Potentially Transformative Autoimmune Therapies
From Candid Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.